Shrugging away the traditional market blues, JB Pharma continues its outstanding growth path by registering impressive numbers for the Financial Year 2021-22 and the First Quarter of the current Financial Year with a growth rate more than 25%, outperforming the market rate of 18% (IQVIA, MAT Jun’22). With operating revenues at INR. 2424 Crores and EBITDA at a strong INR. 550 Crores, JB Pharma is the fastest growing pharmaceutical company in FY 2021-22 and Q1 of FY 2022-23, ranked at No. 23.

Speaking on the performance of the Company, Nikhil Chopra, CEO and Whole Time Director, JB Pharma said, “Our growth has been nothing less than outstanding for the year 2021-22, being ranked in the top 23 pharmaceutical companies in India. We plan on moving quickly up to No. 20, outperforming all market expectations, with strong showing in our domestic business, especially in the core therapy areas.”

In operation for over 45 years, JB Pharma has built a strong foundation of integrity trust and reliability providing quality medicine and strong compliance as per global standards, with a finger firmly on the pulse of world healthcare and evolving customer needs. JB Pharma has been highly successful in creating innovative technologies, therapies and brands preferred by Doctors and Patients across the India and internationally. The new identity is simple, yet solid and is the reflection of the belief in continuing to be Good People for Good Health.

JB Pharma’s rich legacy can be traced right from the year 1976, where the 1st brick in the foundation was laid by the late Mr. J.B. Mody, to the introduction of Metrogyl in the year 1977 which went on to become the Gold Standard in the industry, to the Public listing and expansion from API to Formulations in 1985. In the same year JB forayed into the cardiac segment with the introduction of the path-breaking product, Nicardia, followed by another iconic product Rantac in 1987. The international outreach began as early as 2000 with the launch of OTC brands in Russia for cold and cough, followed by the FDA approval for the Panoli Plant in 2003, strategic investment in Biotech Laboratories of South Africa, and receiving the Silver Award by the United States Pharmacopeia. The year 2007 was also the launch of Cilacar that went on to become the leading brand in cardiology and nephrology, and in the year 2021 came the market beating ranking at No. 28 in the Indian Pharmaceutical companies with 5 brands featuring in the top 300 brands within the country. It was also in 2021 that new therapeutic categories like Diabetes, Nephrology, Respiratory and Virology were also introduced. Acquisition of Azmarda and Sporlac brands was the other major landmark in the first half of 2022.

“Our domestic business has shown significant momentum with the launch of our new Go-to-Market model which has helped us increase productivity bringing greater focus to domestic business. Our entry into the fast-growing chronic segments like heart failure, diabetes and nephrology, along with the launch of 15 new products in the year has helped push up our share of domestic sales in new products by more than 5%. We will continue to consolidate our new acquisitions with the current portfolio and geographical strengths of JB Pharma, towards consistently delivering market beating growth“, Mr. Chopra further added.

While driving the organic growth strategies, JB Pharma has also been open to value-creating opportunities like the three acquisitions that underline the prudent utilization of capital and free cash flows. Sporlac marks the entry into the highly attractive probiotic segment and the acquisition of brand Azmarda from Novartis marks the entry into one of the fastest growing segments within cardiology, that is ‘heart failure’. The acquisition of DRL’s pediatric portfolio further strengthens its equity at pediatricians. The inorganic acquisitions have started showing early wins in JB Pharma, aided by the geographical and therapeutic synergies the company has to offer. Sporlac becomes the No.1 brand in its covered market space in Q1 of Financial year 2022-23.